首页> 外文期刊>Future medicinal chemistry >Liposomal drug delivery systems for targeted cancer therapy: is active targeting the best choice?
【24h】

Liposomal drug delivery systems for targeted cancer therapy: is active targeting the best choice?

机译:用于靶向癌症治疗的脂质体给药系统:主动靶向是最佳选择吗?

获取原文
获取原文并翻译 | 示例
           

摘要

Liposomes are biodegradable and biocompatible self-forming spherical lipid bilayer vesicles. They can encapsulate and deliver one or more hydrophobic and hydrophilic therapeutic agents with poor therapeutic indices to tumor sites. Properties such as lipid bilayer fluidity, charge, size and surface hydration can be modified to extend liposome circulation time in the bloodstream and enhance efficacy. The focus of this review is on ligand-conjugated liposomes and their potential application in tumor-targeted delivery. Ligand-conjugated liposomes are designed to target receptors which are overexpressed on tumor cells to decrease drugs side effects by enhancing their selective delivery to tumor site. Despite the extensive research in this area, no small molecule ligand-conjugated liposome has been approved up to date for cancer therapy.
机译:脂质体是可生物降解的并且具有生物相容性的自形成球形脂质双层囊泡。它们可以将治疗指数差的一种或多种疏水性和亲水性治疗剂包封并递送至肿瘤部位。诸如脂质双层流动性,电荷,大小和表面水合作用的性质可以被修饰以延长脂质体在血液中的循环时间并增强功效。这篇综述的重点是结合配体的脂质体及其在肿瘤靶向递送中的潜在应用。配体缀合的脂质体设计用于靶向在肿瘤细胞上过表达的受体,从而通过增强它们向肿瘤部位的选择性递送来减少药物的副作用。尽管在该领域进行了广泛的研究,但迄今为止尚未批准小分子配体缀合的脂质体用于癌症治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号